BioMarin Pharmaceutical (NASDAQ:BMRN) was upgraded by analysts at TheStreet from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Friday, Analyst Ratings Net reports.
The analysts wrote, “Biomarin Pharmaceutical (BMRN) has been upgraded by TheStreet Ratings from sell to hold. The company’s strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company’s earnings per share, deteriorating net income and disappointing return on equity.”
Shares of BioMarin Pharmaceutical (NASDAQ:BMRN) traded down 0.08% during mid-day trading on Friday, hitting $70.67. The stock had a trading volume of 285,698 shares. BioMarin Pharmaceutical has a 1-year low of $46.53 and a 1-year high of $80.67. The stock has a 50-day moving average of $66.16 and a 200-day moving average of $65.28. The company’s market cap is $10.050 billion.
BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its quarterly earnings results on Thursday, October 24th. The company reported ($0.38) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.30) by $0.08. The company had revenue of $136.90 million for the quarter, compared to the consensus estimate of $140.00 million. During the same quarter in the prior year, the company posted ($0.04) earnings per share. The company’s quarterly revenue was up 6.9% on a year-over-year basis. Analysts expect that BioMarin Pharmaceutical will post $-1.18 EPS for the current fiscal year.
A number of other firms have also recently commented on BMRN. Analysts at Piper Jaffray initiated coverage on shares of BioMarin Pharmaceutical in a research note to investors on Tuesday. They set an “overweight” rating and a $87.00 price target on the stock. Separately, analysts at Barclays reiterated a “buy” rating on shares of BioMarin Pharmaceutical in a research note to investors on Wednesday, November 20th. They now have a $75.00 price target on the stock. Finally, analysts at Wells Fargo & Co. reiterated a “positive” rating on shares of BioMarin Pharmaceutical in a research note to investors on Tuesday, November 19th. Seven investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. BioMarin Pharmaceutical currently has an average rating of “Buy” and a consensus price target of $73.78.
BioMarin Pharmaceutical Inc (NASDAQ:BMRN) develops and commercializes pharmaceuticals for serious diseases and medical conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.